These days, drugs to treat diabetes have one of the highest safety standards to clear before they are granted approval by the Food and Drug Administration (FDA). Placebo-controlled studies are no longer enough to sway agency decision makers. Drug companies must prove their new diabetes treatments won’t cause more problems than the condition they are treating. Which is why excitement over promising data from phase II studies on LY2605541, a joint effort by Eli Lilly and Boehringer Ingelheim, is contained. The drug showed better or equal glycemic control for patients with type 1 or type 2 diabetes than other similar ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.